Specialty Pharmacies Could Be Selling Point If FDA Approves Tasimelteon
Executive Summary
A Nov. 14 advisory committee gave near-unanimous support for Vanda’s sleep disorder drug on questions about its indication, endpoints, efficacy and safety.
You may also be interested in...
Vanda’s Hetlioz Marketing: Disease Awareness DTC, Reps For Specialty Docs
Firm hopes strategy will educate patients about largely unknown condition, non-24 hour sleep-wake disorder, while using small sales force to target sleep experts.
REMS For Qsymia Limits Distribution, But Vivus To Explore Expanding Access
Qsymia will launch through certified mail-order pharmacies, but FDA has asked the sponsor to look for ways to expand into the retail space with pharmacies that can meet requirements for distributing patient risk information and keeping track of prescribers.
Sabril's Approval With REMS No Surprise, But May Provide Marketing Advantage
Periodic vision testing and a restricted distribution program will be required for Lundbeck's spasticity agent.